TY  -  JOUR
AU  -  Gyawali, Bishal
T1  -  Biosimilars in oncology: everybody agrees but nobody uses?
PY  -  2017
Y1  -  2017-04-01
DO  -  10.1701/2681.27452
JO  -  Recenti Progressi in Medicina
JA  -  Recenti Prog Med
VL  -  108
IS  -  4
SP  -  172
EP  -  174
PB  -  Il Pensiero Scientifico Editore
SN  -  2038-1840
Y2  -  2026/05/05
UR  -  http://dx.doi.org/10.1701/2681.27452
N2  -  Summary. Reducing the cost of biologics is an important avenue for addressing financial toxicity in oncology, one of the biggest challenges for health systems. The use of biosimilars, the cheaper alternatives to biologics, is an important strategy to that end. But the enthusiasm of developing biosimilars is meaningless if they get to the market, but they’re not prescribed by the physicians, concerned by unexpected side effects or inferior efficacy. A recent study found no differences between biosimilars and erythropoietin stimulating agents originators in the composite outcome including all-cause mortality, blood transfusion and major cardiovascular events. Such studies are important to allay the concerns of physicians and patients regarding the use of biosimilars. Physician and patient education, backed by clinical guidelines and patient advocacy groups, are the keys to improving the uptake of biosimilars in clinical practice.
ER  -